New formulations of stimulants for attention-deficit hyperactivity disorder: Therapeutic potential

CNS Drugs

Volumn 18, Issue 14, 2004, Pages 1011-1030

  Connor, Daniel F ^a   Steingard, Ronald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DEXEDRIN SPANSULES; DEXMETHYLPHENIDATE; DILTIAZEM; GLIPIZIDE; METHYLPHENIDATE; NIFEDIPINE; OROS; OXYBUTYNIN; PEMOLINE MAGNESIUM; SALBUTAMOL SULFATE; VERAPAMIL;

ABDOMINAL PAIN; ANOREXIA; ATTENTION DEFICIT DISORDER; CHILD HEALTH CARE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPEPSIA; ENANTIOMER; FATIGUE; FEVER; HEADACHE; HEALTH CARE COST; HEALTH EDUCATION; HEMOCONCENTRATION; HUMAN; INSOMNIA; MENTAL PATIENT; NAUSEA; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RHINITIS; STANDARD; SUSTAINED DRUG RELEASE; TREATMENT CONTRAINDICATION; VOMITING; WEIGHT REDUCTION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; HUMANS; METHYLPHENIDATE; STEREOISOMERISM;

EID: 10044221884     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418140-00005     Document Type: Review

References (104)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th rev. ed. Washington, DC: American Psychiatric Press, 1994
2. Barkley RA. International consensus statement on ADHD. Clin Child Fam Psychol Rev 2002; 5: 89-111
3. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001; 107 (3): e43
4. Hinshaw SP. Attention deficits and hyperactivity in children. Thousand Oaks (CA): Sage, 1994
5. US Department of Health and Human Services. Mental health: a report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999
6. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033-44
7. Barkley RA. Attention-deficit hyperactivity disorder. Sci Am 1998; 279: 66-71
8. Anderson JC, Williams S, McGee R, et al. DSM-III disorders in preadolescent children: prevalence in a large sample from the general population. Arch Gen Psychiatry 1987; 44: 69-76
9. Fergusson DM, Horwood LJ, Lynskey MT. Prevalence and comorbidity of DSM-III-R diagnoses in a birth cohort of 15 year olds. J Am Acad Child Adolesc Psychiatry 1993; 32: 1127-34
10. McGee R, Feehan M, Williams S, et al. DSM-III disorders in a large sample of adolescents. J Am Acad Child Adolesc Psychiatry 1990; 29: 611-9
11. Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. Arch Gen Psychiatry 1988; 45: 1120-6
12. Rohde LA. ADHD in Brazil: the DSM-IV criteria in a culturally different population. J Am Acad Child Adolesc Psychiatry 2002; 41: 1131-3
13. Rohde LA, Biederman J, Busnello EA, et al. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. J Am Acad Child Adolesc Psychiatry 1999; 38: 716-22
14. Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry 1995; 34: 629-38
15. Esser G, Schmidt MH, Woerner W. Epidemiology and course of psychiatric disorders in school-age children: results of a longitudinal study. J Child Psychol Psychiatry 1990; 31: 243-63
16. Bhatia MS, Nigam VR, Bohra N, et al. Attention deficit disorder with hyperactivity among paediatric outpatients. J Child Psychol Psychiatry 1991; 32: 297-306
17. Leung PWL, Luk SL, Ho TP, et al. The diagnosis and prevalence of hyperactivity in Chinese schoolboys. Br J Psychiatry 1996; 168: 486-96
18. Kanbayashi Y, Nakata Y, Fujii K, et al. ADHD-related behavior among non-referred children: parents' ratings of DSM-III-R symptoms. Child Psychiatry Hum Dev 1994; 25: 13-29
19. Gadow KD, Nolan EE, Litcher L, et al. Comparison of attention-deficit/ hyperactivity disorder symptom subtypes in Ukrainian schoolchildren. J Am Acad Child Adolesc Psychiatry 2000; 39: 1520-7
20. Verhulst FC, van der Ende J, Ferdinand RP, et al. The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. Arch Gen Psychiatry 1997; 54: 329-36
21. Goldman L, Genel M, Bezman R, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998; 279: 1100-7
22. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998; 59: 4-16
23. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409-32
24. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792-8
25. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36: 21-9
26. Milberger S, Biederman J, Faraone SV, et al. Associations between ADHD and psychoactive substance use disorders: findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997; 6: 318-29
27. Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking: findings from a high-risk sample of siblings. Am J Addict 1997; 6: 205-17
28. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36: 37-44
29. Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between maternal smoking during pregnancy and attention deficit hyperactivity disorder: findings from a high-risk sample of siblings. J Clin Child Psychol 1998; 27: 352-8
30. Leibson C, Katusic S, Barbaresi W, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285: 60-6
31. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 71-8
32. Bijur P, Golding J, Haslum M, et al. Behavioral predictors of injury in school-age children. Am J Dis Child 1988; 142: 1307-12
33. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996; 98: 1089-95
34. Nader PE. School health: policy and practice. Elk Grove Village (IL): American Academy of Pediatrics, 1993
35. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36: 85-121S
36. Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001; 23: 1904-21
37. Connor DF. Aggression and antisocial behavior in children and adolescents: research and treatment. New York: Guilford Press, 2002
38. DuPaul GJ, Stoner G. ADHD in the schools: assessment and intervention strategies. New York: Guilford Press, 1994
39. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 77-97
40. Elia J, Borcherding B, Rapoport J, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders? Psychiatr Res 1991; 36: 141-55
41. Greenhill LL, Findling RL, Swanson JM, et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 109: e39
42. Multimodal Treatment of ADHD Group. Moderators and mediators of treatment response for children with attention-deficit/ hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088-96
43. Arnold LE. Methylphenidate vs amphetamine: comparative review. J Atten Disord 2000; 3: 200-11
44. Greenhill LL, Abikoff H, Arnold LE, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35: 1304-13
45. Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 857-64
46. Laufer MW, Denhoff E, Solomons G. Hyperkinetic impulse disorder in children's behavior problems. Psychosom Med 1957; 19: 38-49
47. Fischer M, Barkley RA, Smallish L, et al. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002; 30: 463-75
48. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816-8
49. Biederman J, Milberger S, Faraone SV, et al. Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 1495-503
50. Jensen PS. ADHD: current concepts on etiology, pathophysiology, and neurobiology. Child Adolesc Psychiatr Clin N Am 2000; 9: 557-72
51. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry 1991; 25: 277-83
52. Zametkjn A, Liotta W. The neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 1998; 59: 17-23
53. Posner MI, Raichle ME. Images of mind. Rev. ed. Washington, DC: Scientific American Books, 1996
54. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127-52
55. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000; 9: 573-603
56. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35: 264-72
57. Barkley RA, DuPaul GJ, Connor DF. Stimulants. In: Werry JS, Aman MG, editors. Practitioner's guide to psychoactive drugs for children and adolescents. New York: Plenum Medical Book Company, 1999: 213-47
58. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44: 951-8
59. Pliszka SR. Neuroscience for the mental health clinician. New York: Guilford Press, 2003: 279
60. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52: 456-63
61. Wilens TE, Spencer TJ. Pharmacology of amphetamines. In: Tarter RE, Ammerman RT, Ott PJ, editors. Handbook of substance abuse neurobehavioral pharmacology. New York: Plenum Press, 1998: 501-13
62. Diener RM. Toxicology of ritalin. In: Greenhill LL, Osman BB, editors. Ritalin theory and patient management. New York: Mary Ann Liebert Inc., 1991: 35-43
63. Pelham WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987; 80: 491-501
64. Pelham WE, Swanson JM, Furman MB, et al. Pemoline effects on children with ADHD: a time-response by dose- response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995; 34: 1504-13
65. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 199-248
66. Caldwell J, Sever PS. The biochemical pharmacology of abused drugs. Clin Pharmacol Ther 1974; 16: 625-38
67. Greenhill LL. Attention deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin N Am 1995; 4: 123-68
68. Birmaher B, Greenhill LL, Cooper TB, et al. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989; 28: 768-72
69. Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry 2002; 63: 656-7
70. Huang W, Gao Q, Harris M, et al. Separation of ritalin racemate and its by-product racemates by capillary electrophoresis. Electrophoresis 2001; 22: 3226-31
71. Ferris R, Tang F. Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradol on the uptake of 1-[3H]-norepinephrineand [3H]-dopamineby synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther 1979; 210: 422-8
72. Eckerman DA, Moy SS, Perkins AN, et al. Enantioselective behavioral effects of threo-methylphenidate in rats. Pharmacol Biochem Behav 1991; 40: 875-80
73. Novartis Pharmaceuticals. Focalin product monograph. East Hanover (NJ): Novartis Pharmaceuticals, 2002: 5-19
74. Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and 1-threomethylphenidate in the human and baboon brain. Psychopharmacology (Berl) 1997; 131: 71-8
75. Srinivas NR, Hubbard JA, Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of d1-threo-methylphenidate in children with attention deficit disorder. Clin Pharmacol Ther 1992; 52: 561-8
76. Dexmethylphenidate (Focalin) for ADHD. The Medical Letter 2002; 44 (1130): 45-6
77. Safer DJ, Zito JM, Gardner JF. Pemoline hepatotocxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 2001; 40: 622-9
78. McNeil Pharmaceuticals. Concerta product monograph. Fort Washington (PA): 2001: 2-28
79. ALZA Technologies. Concerta™: a success story [online] Available from URL: http://www.alza.com/pdf/vol_1_1.pdf [Accessed 2004 Oct 1]. Delivery Times 2001; 1 (1)
80. Data on file, Adderall XR. Shire US Inc., 2001
81. Novartis Pharmaceuticals. Ritalin LA Product Monograph. East Hanover (NJ): Novartis Pharmaceuticals, 2002
82. Grcevich S. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs 2001; 10: 2003-11
83. Faraone SV, Pliszka SR, Olvera RL, et al. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology. J Child Adolesc Psychopharmacol 2001; 11: 171-80
84. Keating GM, McClellan K, Jarvis B. Methylphenidate (OROS Formulation). CNS Drugs 2001; 15: 495-500
85. Auiler JF, Liu JM, Lynch JM, et al. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation (CAFE) study. Curr Med Res Opin 2002; 18: 311-6
86. Pentikis HS, Simmons RD, Benedict MF, et al. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 2002; 41: 443-9
87. Michaels MA, Weston IE, Zhang Y, et al. Pharmacokinetics of SLI381, a two-component extended-release formulation of mixed amphetamine salts, administered in fasted and fed states, and sprinkled on food. Phoenix (AZ): New Clinical Drug Evaluation Unit, 2001 May 29
88. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: 1-15
89. Wolraich ML, Greenhill LL, Pelham WE, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001; 108: 883-92
90. Swanson JM, Wigal SB, Lerner MA, et al. Comparison of the efficacy and safety of OROS methylphenidate HCL with methylphenidate tid and placebo in children with ADHD [abstract]. Pediatr Res 2000; 47: 199
91. Wilens T, Pelham WE, Stein MT, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003; 42: 424-33
92. McCracken JT, McGough JJ, Biederman J, et al. Analogue classroom assessment of SLI381 for the treatment of ADHD [presentation]. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2000 Oct, New York
93. Biederman J, Lopez F, Boellner S, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 110: 258-66
94. Biederman J, Lopez F, Boellner S, et al. A randomized controlled trial of once-daily-dosed Adderall XR for the treatment of ADHD. Boston (MA): US Psychiatric and Mental Health Congress, 2001 Nov
95. th Annual Meeting of the American Psychiatric Association; Philadelphia (PA); 2002 May 22
96. Celltech Development. Protocol No. 1001-02. Wayne (PA): Celltech Development, 2002
97. Boellner S, Tulloch SJ, Zhang Y. A single-dose bioequivalence study comparing 1 x 30mg capsule of SLI 381 to 3 x 10mg capsules of SLI 381 in pediatric subjects. Phoenix (AZ): New Clinical Drug Evaluation Unit, 2002 May 29
98. Swanson JM, Greenhill LL, Pelham WE, et al. Initiating Concerta (OROS methylphenidate HCL) qd in children with attention-deficit/hyperactivity disorder. J Clin Res 2000; 3: 59-76
99. James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40: 1268-76
100. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose response study. Pediatrics 2001; 108: 1-9
101. Wilens TE, Biederman J, Mick E, et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185: 475-82
102. Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug abuse? A 13-year prospective study. Pediatrics 2003; 111: 97-109
103. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 11: 179-85
104. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict 1998; 7: 156-63